

Pamidronate Disodium Injection



PRESENTATIONS

30mg

NDC# 59923-601-10

90mg

#59923-603-10

AP Bioequivalent Parenteral Product

J-Code: J2430

bar coded product

STORAGE

Pamidronate disodium should be stored at room temperature, but not to exceed 86° F

NOT A REFRIGERATED PRODUCT

TECHNICAL INFORMATION

Customer Service (855) 853-4760

Package insert available at
arevapharma.com

ORDER

Direct and wholesaler orders accepted

WHOLESOME APPROACH TO HEALTHCARE

Areva Pharmaceuticals
arevapharma.com

Product enlarged for detail. See the back panel for actual label size.

© 2013 Areva Pharmaceuticals 11/13

Pamidronate Disodium Product Packaging

For complete product information visit arevapharma.com



Actual Size




Actual Size

30 mg single-use vial

Each 30-mg vial contains 30 mg of sterile, lyophilized pamidronate disodium and 470 mg of mannitol, USP.

Carton Dimensions

32mm (W) x 65mm (H) x 28mm (D)



Actual Size




Actual Size

90 mg single-use vial

Each 90-mg vial contains 90 mg of sterile lyophilized pamidronate disodium and 375 mg of mannitol, USP.

Carton Dimensions

32mm (W) x 65mm (H) x 28mm (D)



Storage conditions: Pamidronate disodium should be stored at a controlled room temperature, but not to exceed 86° F. This is NOT A REFRIGERATED PRODUCT. **Preparation of Solution: Reconstitution** - Pamidronate disodium for Injection USP is reconstituted by adding 10 mL of Sterile Water for Injection, USP, to each vial, resulting in a solution of 30 mg/10 mL, 60mg/10mL or 90 mg/10 mL. The pH of the reconstituted solution is 6.0-7.4. The drug should be completely dissolved before the solution is withdrawn. The reconstituted solution may be stored under refrigeration at 2°C-8°C (36°F-46°F) for up to 24 hours. **Method of Administration:** DUE TO THE RISK OF CLINICALLY SIGNIFICANT DETERIORATION IN RENAL FUNCTION, WHICH MAY PROGRESS TO RENAL FAILURE, SINGLE DOSES OF PAMIDRONATE DISODIUM FOR INJECTION USP SHOULD NOT EXCEED 90 MG. (SEE WARNINGS) There must be strict adherence to the intravenous administration recommendations for Pamidronate disodium for Injection USP in order to decrease the risk of deterioration in renal function.